After activist investor Elliot Associates disclosed a 9.3% stake in athenahealth, Piper Jaffray analyst Sean Wieland said he agrees "wholeheartedly" that the shares are undervalued, but he contends that selling the company at this point does not line up well with the goals of stakeholders and would be no more than a "get rich quick" strategy. The analyst, in a note entitled "Nobody Puts Johnny in a Corner," said the company's takeover defenses are strong and he believes the greatest opportunity is to let founder and CEO Jonathan Bush work on disrupting the status quo in healthcare. However, if Elliott could help implement more operational discipline, "everyone wins," said Wieland, who keeps an Overweight rating on the shares.